New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:04 EDTISISIsis Pharmaceuticals announces results of antisense targeting of HBV
Isis Pharmaceuticals announced that treatment with an antisense compound targeting hepatitis B virus produced dose-dependent reductions in all measured liver and serum viral markers of HBV infection in animal models of HBV infection. These preclinical data demonstrate that antisense targeting of HBV RNA could be an effective approach to treating patients with chronic HBV infection. In this study, an antisense compound targeting HBV produced dose-dependent reductions of HBV-associated antigens, including HBsAg, which is present in both acute and chronic infections and is associated with a poor prognosis in patients with chronic HBV infection. In addition, other measures of viral infection were reduced in both the liver and serum in this mouse model of disease.
News For ISIS From The Last 14 Days
Check below for free stories on ISIS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 17, 2014
07:10 EDTISISIsis Pharmaceuticals begins Phase 2 study of candidate for high lipoprotein(a)
Subscribe for More Information
July 16, 2014
07:14 EDTISISIsis Pharmaceuticals earns $1M milestone payment from GlaxoSmithKline
Isis Pharmaceuticals (ISIS) has earned a $1M milestone payment from GlaxoSmithKline (GSK) related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve and/or heart tissues. Including this milestone payment, Isis has generated $27M in upfront and milestone payments for advancing ISIS-TTRRx. If GSK elects to exercise its option to exclusively license the ISIS-TTRRx program, Isis is eligible to receive a license fee, regulatory and sales milestone payments and double-digit royalties on sales of ISIS-TTRRx.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use